Dismissal Of Teva Suit Triggered Ticlopidine 180-Days, Appeals Court Rules
Executive Summary
Torpharm's 180-day ticlopidine exclusivity was triggered by the June 1998 dismissal of Teva's declaratory judgment action against Roche in California federal court, the D.C. federal appeals court ruled July 20.
You may also be interested in...
FDA Favors Narrow Interpretation Of Exclusivity Court Decision Triggers
FDA's narrow policy on court decision triggers for 180-day exclusivity could increase the value of the generic exclusivity incentive, the agency says
FDA Favors Narrow Interpretation Of Exclusivity Court Decision Triggers
FDA's narrow policy on court decision triggers for 180-day exclusivity could increase the value of the generic exclusivity incentive, the agency says
Pravachol Exclusivity: Teva Wins By Winning– FDA Wins By Losing?
A recent D.C. federal appeals court decision affirming Teva's exclusivity period for Pravachol generics opens the door for new standard-setting by FDA on what conditions trigger the start of 180-day exclusivity